Skip to main content

Long-term protection of hepatitis B vaccine in HIV-infected patients


Many studies reported in HIV-positive patients 50% of hepatitis B vaccine response with a duration of protection between 24 and 36 months. The aim of our study is to determine the long term protection in our HIV patients who responded to a standard immunization schedule.

Materials and methods

Our database NADIS allows us to collect information from March 1986 to October 2013 (gender, age, CD4 count, HIVRNA and Hepatitis B surface antibody titers = HBs Ab > 10 IU / L.)

Patients were included gradually after 3 Engerix B 20 hepatitis B vaccines at day 1, one month and 6 months later, conferring a rate of HBs ab > 10 IU /L. Then we observed the duration of protection from the initial response.


Among 403 HIV patients who responded to HBV, 298 were men (74%) vs 105 women (26%). The median age was 36 years. We observed a progressive decline in HBs ab titer until <10 IU/ L. At 24 months 74.7% (n=223) men remained protected vs 79.2% (n=83) women. At 60 months. 33.1% (n=99) men lost their HB protection vs 27.7% (n=29) women (LR = 0,11 NS).

At 84 months and over 120 months, 34.7% (n=103) and 39.1% (n=117) men lost their HB protection vs 35.8% (n=38) and 38.2% women (n=40).


Long term HBV protection was observed in the majority of our HIV patients. One third had lost their HBs ab after 2 years, and require HB boost injections. We are thinking of using an adjuvanted HB vaccine as a booster to provide a sustained protection. We will also study factors associated with the loss of HBV protection.

Figure 1
figure 1

Duration of HBV protection (months)

Author information

Authors and Affiliations


Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Biekre, R., Lasfar, N.B., Viget, N. et al. Long-term protection of hepatitis B vaccine in HIV-infected patients. BMC Infect Dis 14 (Suppl 2), O7 (2014).

Download citation

  • Published:

  • DOI: